Neumora Therapeutics (NMRA) Other Accumulated Expenses (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Other Accumulated Expenses of $736000.0 for Q1 2026, up 79.95% year-over-year from $409000.0 in Q1 2025, and up 1.66% quarter-over-quarter from $724000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $736000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 79.95% year-over-year to $736000.0; the TTM figure through Mar 2026 stood at $736000.0 (up 79.95% YoY), while the FY2025 annual figure was $724000.0, up 122.09% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $736000.0, up from $724000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $750000.0 in Q4 2023, with the low at $326000.0 in Q4 2024.
- The 5-year median for Other Accumulated Expenses is $429000.0 (2025), against an average of $493916.7.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 56.53% in 2024, then surged 122.09% in 2025.
- Neumora Therapeutics' Other Accumulated Expenses stood at $408000.0 in 2022, then surged by 83.82% to $750000.0 in 2023, then tumbled by 56.53% to $326000.0 in 2024, then soared by 122.09% to $724000.0 in 2025, then climbed by 1.66% to $736000.0 in 2026.
- Business Quant data shows NMRA's Other Accumulated Expenses at $736000.0 in Q1 2026, $724000.0 in Q4 2025, and $449000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 736,000.00 |
| Dec 31, 2025 | 724,000.00 |
| Sep 30, 2025 | 449,000.00 |
| Jun 30, 2025 | 450,000.00 |
| Mar 31, 2025 | 409,000.00 |
| Dec 31, 2024 | 326,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 366,000.00 |
| Mar 31, 2024 | 542,000.00 |
| Dec 31, 2023 | 750,000.00 |
| Sep 30, 2023 | 375,000.00 |
| Dec 31, 2022 | 408,000.00 |